What does this research mean for the field?

PSB202, a first-in-class bifunctional antibody co-targeting CD20 and CD37, demonstrates a manageable safety profile without cytokine release syndrome and shows preliminary clinical efficacy in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.ESTABLISHES_NEW_DIRECTION.

What question did this study set out to answer?

This trial aims to evaluate the safety and efficacy of PSB202, a bifunctional antibody targeting CD20 and CD37 in relapsed or refractory B-cell malignancies.

May 31, 2026Journal of Hematology & OncologyOpen Access

A first-in-class bifunctional antibody targeting CD20 and CD37 remodels the immune microenvironment in relapsed or refractory B-cell malignancies

View Full Paper

Ask AI

Bookmark

Authors

LWLi WangRuijin Hospital JLJ S LiuEast China Jiaotong University KZKeshu ZhouZhengzhou University

Discussion

Member takes

Implication

Randomized trial demonstrates safety and efficacy of PSB202 in relapsed or refractory B-cell malignancies, suggesting a new treatment approach.

Key Points

This trial aims to evaluate the safety and efficacy of PSB202, a bifunctional antibody targeting CD20 and CD37 in relapsed or refractory B-cell malignancies.
Multicenter, open-label phase Ia trial (NCT05003141)
Adults with relapsed or refractory CD20+ B-cell non-Hodgkin lymphoma received PSB202 in escalating doses from 12 to 300 mg
Primary endpoints included dose-limiting toxicities and maximum tolerated dose.
One dose-limiting toxicity of grade 4 neutropenia occurred at 100 mg
Overall response rate was 30% in evaluable patients, including one complete response at 300 mg
PSB202 led to sustained B-cell depletion and induced IFN-γ release without cytokine release syndrome.

Cite This Study

Wang et al. (2026) studied this question.

synapsesocial.com/papers/6a1bd21d5783ba022b6fd7db https://doi.org/10.1186/s13045-026-01796-5

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial demonstrates safety and efficacy of PSB202 in relapsed or refractory B-cell malignancies, suggesting a new treatment approach.

A first-in-class bifunctional antibody targeting CD20 and CD37 remodels the immune microenvironment in relapsed or refractory B-cell malignancies

Discussion

Member takes

Implication

Key Points

Cite This Study

A first-in-class bifunctional antibody targeting CD20 and CD37 remodels the immune microenvironment in relapsed or refractory B-cell malignancies

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider